MDxHealth S.A.·Healthcare

MDxHealth SA (NASDAQ: MDXH - Get Free Report) has earned a consensus rating of "Moderate Buy" from the five research firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12 month target price

MDxHealth (NASDAQ: MDXH - Get Free Report) and Health Catalyst (NASDAQ: HCAT - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings and dividends. Volatility and Risk MDxHealth has a beta of

Mdxhealth Highlights Data from Oxford's ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026

MDxHealth SA (MDXH) Q4 2025 Earnings Call Transcript

Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26 Company to Host Conference Call with Live Q&A, February 26, 2026, at 4:30pm ET / 22:30 CET IRVINE, California – February 12, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2025, after market close on Thursday, February 26, 2026. Title: Mdxhealth Presents Fourth Quarter and Full Year 2025 Financial Results andCorporate Update Conference Call and Webcast Date: February 26, 2026 Time: 4:30pm ET/ 22:30 CET Conference Call D ial-in Details: United States: 1-844-825-9789 Int'l: 1-412-317-5180 Belgium: 0800 38 961 United Kingdom: 0800 279 9489 Conference ID: 10206764 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1753070&tp_key=27bce7d4de The webcast should be accessed 15 minutes prior to the conference call start time.

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Healthcare
Medical - Diagnostics & Research
312
2021-11-04
0.38